316 related articles for article (PubMed ID: 25964641)
1. Hodgkin lymphoma, version 2.2015.
Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bierman PJ; Blum KA; Chen R; Dabaja B; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hochberg EP; Huang J; Johnston PB; Khan N; Maloney DG; Mauch PM; Metzger M; Moore JO; Morgan D; Moskowitz CH; Mulroney C; Poppe M; Rabinovitch R; Seropian S; Tsien C; Winter JN; Yahalom J; Burns JL; Sundar H;
J Natl Compr Canc Netw; 2015 May; 13(5):554-86. PubMed ID: 25964641
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bernat K; Bierman PJ; Blum KA; Chen R; Dabaja B; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hochberg EP; Huang J; Johnston PB; Kaminski MS; Kenkre VP; Khan N; Maloney DG; Mauch PM; Metzger M; Moore JO; Morgan D; Moskowitz CH; Mulroney C; Poppe M; Rabinovitch R; Seropian S; Smith M; Winter JN; Yahalom J; Burns J; Ogba N; Sundar H
J Natl Compr Canc Netw; 2017 May; 15(5):608-638. PubMed ID: 28476741
[TBL] [Abstract][Full Text] [Related]
3. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
4. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
5. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2016 Jun; 91(4):434-42. PubMed ID: 27001163
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2020 Aug; 95(8):978-989. PubMed ID: 32384177
[TBL] [Abstract][Full Text] [Related]
8. SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.
Rueda Domínguez A; Alfaro Lizaso J; de la Cruz Merino L; Gumá I Padró J; Quero Blanco C; Gómez Codina J; Llanos Muñoz M; Martinez Banaclocha N; Rodriguez Abreu D; Provencio Pulla M
Clin Transl Oncol; 2015 Dec; 17(12):1005-13. PubMed ID: 26497354
[TBL] [Abstract][Full Text] [Related]
9. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
[TBL] [Abstract][Full Text] [Related]
11. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2014 Jul; 89(7):771-9. PubMed ID: 24953862
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
15. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
16. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Moskowitz AJ; Herrera AF; Beaven AW
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2022 Nov; 97(11):1478-1488. PubMed ID: 36215668
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin lymphoma.
Gobbi PG; Ferreri AJ; Ponzoni M; Levis A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):216-37. PubMed ID: 22867814
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and staging of Hodgkin lymphoma].
Ghesquières H
Rev Prat; 2023 Jun; 73(6):617-620. PubMed ID: 37458549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
